Compounds > N1-[4-(aminosulfonyl)phenyl]-2,2-dimethylpropanamide
Page last updated: 2024-12-09

N1-[4-(aminosulfonyl)phenyl]-2,2-dimethylpropanamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID2725651
CHEMBL ID23285
CHEMBL ID-23285
CHEBI ID190540
SCHEMBL ID10603454

Synonyms (26)

Synonym
OPREA1_396828
bdbm16649
aromatic sulfonamide compound 14
chembl23285 ,
4-pivaloylamido-benzenesulfonamide
2,2-dimethyl-n-(4-sulfamoylphenyl)propanamide
n-(4-sulfamoylphenyl)pivalamide
n1-[4-(aminosulfonyl)phenyl]-2,2-dimethylpropanamide
CHEBI:190540
103826-87-5
2,2-dimethyl-n-(4-sulamoylphenyl)propanamide
AKOS003441276
CCG-916
KGBTVIQRHXYTRQ-UHFFFAOYSA-N
p-pivaloylaminobenzenesulfonamide
SCHEMBL10603454
Z27682730
BRD-K77020128-001-01-6
propanamide, n-(4-(aminosulfonyl)phenyl)-2,2-dimethyl-
2,2-dimethyl-n-(4-sulfamoylphenyl)propionamide
KXQ5HR3BJH ,
n-(4-(aminosulfonyl)phenyl)-2,2-dimethylpropanamide
chembl-23285
unii-kxq5hr3bjh
PD180110
EN300-257376
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 12Homo sapiens (human)Ki0.24900.00021.10439.9000AID254245
Carbonic anhydrase 1Homo sapiens (human)Ki10.08230.00001.372610.0000AID1797528; AID254242; AID50350; AID601813
Carbonic anhydrase 2Homo sapiens (human)Ki3.77660.00000.72369.9200AID1797528; AID254243; AID47898; AID601814
Carbonic anhydrase 5A, mitochondrialMus musculus (house mouse)Ki5.86900.00300.45603.0000AID1797528
Carbonic anhydrase 7Homo sapiens (human)Ki7.20000.00021.37379.9000AID601815
Carbonic anhydrase 9Homo sapiens (human)Ki0.13600.00010.78749.9000AID254244
Carbonic anhydrase 4Bos taurus (cattle)Ki5.20520.00300.59349.6500AID1797528; AID48119
Carbonic anhydrase 14Homo sapiens (human)Ki0.73000.00021.50999.9000AID601816
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (17)

Processvia Protein(s)Taxonomy
estrous cycleCarbonic anhydrase 12Homo sapiens (human)
chloride ion homeostasisCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 12Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 7Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 7Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 7Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 7Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 7Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 7Homo sapiens (human)
response to hypoxiaCarbonic anhydrase 9Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 9Homo sapiens (human)
response to xenobiotic stimulusCarbonic anhydrase 9Homo sapiens (human)
response to testosteroneCarbonic anhydrase 9Homo sapiens (human)
secretionCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 9Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
zinc ion bindingCarbonic anhydrase 12Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 12Homo sapiens (human)
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 7Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 9Homo sapiens (human)
protein bindingCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 9Homo sapiens (human)
molecular function activator activityCarbonic anhydrase 9Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 4Bos taurus (cattle)
zinc ion bindingCarbonic anhydrase 14Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
membraneCarbonic anhydrase 12Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 12Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 12Homo sapiens (human)
plasma membraneCarbonic anhydrase 12Homo sapiens (human)
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 7Homo sapiens (human)
cytoplasmCarbonic anhydrase 7Homo sapiens (human)
nucleolusCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
membraneCarbonic anhydrase 9Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 9Homo sapiens (human)
microvillus membraneCarbonic anhydrase 9Homo sapiens (human)
plasma membraneCarbonic anhydrase 9Homo sapiens (human)
side of membraneCarbonic anhydrase 4Bos taurus (cattle)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
membraneCarbonic anhydrase 14Homo sapiens (human)
basolateral plasma membraneCarbonic anhydrase 14Homo sapiens (human)
apical plasma membraneCarbonic anhydrase 14Homo sapiens (human)
plasma membraneCarbonic anhydrase 14Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (47)

Assay IDTitleYearJournalArticle
AID482524Anticonvulsant activity in po dosed CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482525Protective index, ratio of TD50 for CF1 albino mouse to ED50 for subcutaneous pentylenetetrazole-induced CF1 albino seizure mouse model2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID47898Inhibition of human cytosolic isozyme Carbonic anhydrase II at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID254243Inhibitory activity against human Carbonic anhydrase II (hCA II)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID482734Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482514Neurotoxicity in CF1 albino mouse assessed as motor impairment at 100 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID254244Inhibitory activity against human Carbonic anhydrase IX (hCA IX)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID482732Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482558Teratogenic effect in SWV mouse assessed as live fetuses at 282 mg/kg, ip administered on morning of day 8 of gestation2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482513Neurotoxicity in CF1 albino mouse assessed as motor impairment at 30 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482733Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID48309Inhibition of murine mitochondrial isozyme Carbonic anhydrase V at 20 degrees C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID482726Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID50350Inhibition of cloned human cytosolic isozyme Carbonic anhydrase I2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID482510Neurotoxicity in CF1 albino mouse assessed as motor impairment at 30 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID601815Inhibition of human carbonic anhydrase 7 preincubated with compound for 15 mins by carbon dioxide hydration assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.
AID482526Neurotoxicity in po dosed CF1 albino mouse assessed as motor impairment2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482522Anticonvulsant activity in po dosed CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482730Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 30 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482517Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, po after 30 mins2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482532Teratogenic effect in SWV mouse assessed as resorptions at 282 mg/kg, ip administered on morning of day 8 of gestation2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482520Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, po after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482729Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 300 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID232688Selectivity ratio of KI, human carbonic anhydrase II (hCA II), to that of KI, mouse carbonic anhydrase V (mCA V)2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID482515Neurotoxicity in CF1 albino mouse assessed as motor impairment at 300 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID484090Teratogenic effect in SWV mouse assessed as fetuses with neural tube deffects at 141 mg/kg, ip administered on morning of day 8 of gestation2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482523Protective index, ratio of TD50 for CF1 albino mouse to ED50 for maximal electroshock-induced CF1 albino seizure mouse model2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482516Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, po after 15 mins2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID601816Inhibition of human carbonic anhydrase 14 preincubated with compound for 15 mins by carbon dioxide hydration assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.
AID484089Teratogenic effect in SWV mouse assessed as fetuses with neural tube deffects at 282 mg/kg, ip administered on morning of day 8 of gestation2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482533Teratogenic effect in SWV mouse assessed as resorptions at 141 mg/kg, ip administered on morning of day 8 of gestation2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482559Teratogenic effect in SWV mouse assessed as live fetuses at 141 mg/kg, ip administered on morning of day 8 of gestation2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID254242Inhibitory activity against human Carbonic anhydrase I (hCA I)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID482521Neurotoxicity in CF1 albino mouse assessed as motor impairment at 30 mg/kg, po after 0.25 to 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID601813Inhibition of human carbonic anhydrase 1 preincubated with compound for 15 mins by carbon dioxide hydration assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.
AID601817Anticonvulsant activity against maximal electroshock-induced seizures in po dosed rat2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.
AID254245Inhibitory activity against human Carbonic anhydrase XII (hCA XII)2005Bioorganic & medicinal chemistry letters, Nov-01, Volume: 15, Issue:21
Carbonic anhydrase inhibitors: inhibition of the tumor-associated isozymes IX and XII with a library of aromatic and heteroaromatic sulfonamides.
AID601814Inhibition of human carbonic anhydrase 2 preincubated with compound for 15 mins by carbon dioxide hydration assay2011Journal of medicinal chemistry, Jun-09, Volume: 54, Issue:11
Anticonvulsant 4-aminobenzenesulfonamide derivatives with branched-alkylamide moieties: X-ray crystallography and inhibition studies of human carbonic anhydrase isoforms I, II, VII, and XIV.
AID482509Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 300 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID48119Inhibition of bovine membrane bound isozyme carbonic anhydrase IV isolated from microsomes at 20 degree C2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID482727Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 4 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482724Anticonvulsant activity in CF1 albino mouse assessed as inhibition of maximal electroshock-induced seizures at 30 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID482731Anticonvulsant activity in CF1 albino mouse assessed as inhibition of subcutaneous pentylenetetrazole-induced seizures at 100 mg/kg, ip after 0.5 hrs2010Journal of medicinal chemistry, May-27, Volume: 53, Issue:10
Syntheses and evaluation of anticonvulsant profile and teratogenicity of novel amide derivatives of branched aliphatic carboxylic acids with 4-aminobenzensulfonamide.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1797528Esterase Assay from Article 10.1021/jm031057+: \\Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.\\2004Journal of medicinal chemistry, Feb-26, Volume: 47, Issue:5
Carbonic anhydrase inhibitors. Inhibition of mitochondrial isozyme V with aromatic and heterocyclic sulfonamides.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (28.57)29.6817
2010's4 (57.14)24.3611
2020's1 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetazolamide
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)		2.7230monocarboxylic acid amide;
sulfonamide;
thiadiazoles		anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
dichlorphenamide
Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.		2.0210dichlorobenzene;
sulfonamide		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug
valproic acid
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.		2.0510branched-chain fatty acid;
branched-chain saturated fatty acid		anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent
ethoxzolamide
Ethoxzolamide: A carbonic anhydrase inhibitor used as diuretic and in glaucoma. It may cause hypokalemia.. ethoxzolamide : A sulfonamide that is 1,3-benzothiazole-2-sulfonamide which is substituted by an ethoxy group at position 6. A carbonic anhydrase inhibitor, it has been used in the treatment of glaucoma, and as a diuretic.		2.4220aromatic ether;
benzothiazoles;
sulfonamide		antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
mafenide
Mafenide: A sulfonamide that inhibits the enzyme CARBONIC ANHYDRASE and is used as a topical anti-bacterial agent, especially in burn therapy.		2.0210aromatic amine
methazolamide
Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.		2.0210sulfonamide;
thiadiazoles
sulfanilamide
[no description available]		2.4220substituted aniline;
sulfonamide antibiotic;
sulfonamide		antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
zonisamide
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.		2.06101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
sulfacetamide
[no description available]		2.4220
brinzolamide
brinzolamide: an antiglaucoma agent		2.0210sulfonamide;
thienothiazine		antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
4-(2-aminoethyl)benzenesulfonamide
[no description available]		2.0210
dorzolamide
dorzolamide: topically effective ocular hypotensive carbonic anhydrase inhibitor; RN refers to mono-HCl (4S-trans)-isomer. dorzolamide : 5,6-Dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide in which hydrogens at the 4 and 6 positions are substituted by ethylamino and methyl groups, respectively (4S, trans-configuration). A carbonic anhydrase inhibitor, it is used as the hydrochloride in ophthalmic solutions to lower increased intraocular pressure in the treatment of open-angle glaucoma and ocular hypertension.		2.0210sulfonamide;
thiophenes		antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor
topiramate
Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.		2.4420cyclic ketal;
ketohexose derivative;
sulfamate ester		anticonvulsant;
sodium channel blocker
ConditionIndicatedRelationship StrengthStudiesTrials
Acrania
[description not available]		02.0510
Absence Seizure
[description not available]		02.0510
Neural Tube Defects
Congenital malformations of the central nervous system and adjacent structures related to defective neural tube closure during the first trimester of pregnancy generally occurring between days 18-29 of gestation. Ectodermal and mesodermal malformations (mainly involving the skull and vertebrae) may occur as a result of defects of neural tube closure. (From Joynt, Clinical Neurology, 1992, Ch55, pp31-41)		02.0510
Seizures
Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.		02.0510
Aura
[description not available]		02.0610
Epilepsy
A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)		02.0610
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110
Anemia, Fanconi
[description not available]		02.1310
Fanconi Anemia
Congenital disorder affecting all bone marrow elements, resulting in ANEMIA; LEUKOPENIA; and THROMBOPENIA, and associated with cardiac, renal, and limb malformations as well as dermal pigmentary changes. Spontaneous CHROMOSOME BREAKAGE is a feature of this disease along with predisposition to LEUKEMIA. There are at least 7 complementation groups in Fanconi anemia: FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, and FANCL. (from Online Mendelian Inheritance in Man, http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=227650, August 20, 2004)		02.1310